O-(2-[18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications
KJ Langen, K Hamacher, M Weckesser, F Floeth… - Nuclear medicine and …, 2006 - Elsevier
O-(2-[ 18 F]fluoroethyl)-l-tyrosine (FET) is a promising tracer for PET that has demonstrated
convincing results especially in the diagnostics of brain tumors. In contrast to other …
convincing results especially in the diagnostics of brain tumors. In contrast to other …
Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT
…, HH Scheld, O Schober, M Weckesser - Journal of Nuclear …, 2012 - Soc Nuclear Med
In the diagnostic algorithm of cardiac tumors, the noninvasive determination of malignancy
and metastatic spread is of major interest to stratify patients and to select and monitor …
and metastatic spread is of major interest to stratify patients and to select and monitor …
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in …
…, JM Zijlstra, A Bockisch, M Weckesser… - Blood, The Journal …, 2008 - ashpublications.org
In the HD15 trial of the German Hodgkin Study Group, the negative predictive value (NPV)
of positron emission tomography (PET) using [ 18 F]-fluorodeoxyglucose in advanced-stage …
of positron emission tomography (PET) using [ 18 F]-fluorodeoxyglucose in advanced-stage …
[HTML][HTML] The diagnostic imaging of bone metastases
W Heindel, R Gübitz, V Vieth, M Weckesser… - Deutsches Ärzteblatt …, 2014 - ncbi.nlm.nih.gov
Background Skeletal metastases are the most common malignant tumor in bone. Certain
types of cancer (eg, of the prostate or breast) are particularly likely to give rise to skeletal …
types of cancer (eg, of the prostate or breast) are particularly likely to give rise to skeletal …
Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer
K Rahbar, A Bode, M Weckesser… - Clinical nuclear …, 2016 - journals.lww.com
Background Despite progress in treatment of metastatic castration-resistant prostate cancer (mCRPC),
new approaches are urgently needed. Recently theranostic concepts using …
new approaches are urgently needed. Recently theranostic concepts using …
Positron emission tomography–guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial
…, C Franzius, F Kroschinsky, M Weckesser… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Interim positron emission tomography (PET) using the tracer, [ 18 F]fluorodeoxyglucose,
may predict outcomes in patients with aggressive non-Hodgkin lymphomas. We …
may predict outcomes in patients with aggressive non-Hodgkin lymphomas. We …
Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer
K Rahbar, M Weckesser, S Huss… - Journal of Nuclear …, 2016 - Soc Nuclear Med
We evaluated the diagnostic value and accuracy of prostate-specific membrane antigen (PSMA)
PET for the intraprostatic delineation of prostate cancer before prostatectomy. Methods: …
PET for the intraprostatic delineation of prostate cancer before prostatectomy. Methods: …
[HTML][HTML] The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on …
…, T Niederstadt, T Zoubi, M Weckesser… - …, 2016 - journals.lww.com
BACKGROUND: Approximately 20% of grade II and most grade III gliomas fluoresce after 5-aminolevulinic
acid (5-ALA) application. Conversely, approximately 30% of nonenhancing …
acid (5-ALA) application. Conversely, approximately 30% of nonenhancing …
[HTML][HTML] PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric …
…, J Kleesiek, M Schäfers, M Weckesser… - European Journal of …, 2021 - Springer
Introduction [ 177 Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment
option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy …
option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy …
[HTML][HTML] Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy
…, K Kessel, M Schäfers, J Kleesiek, M Weckesser… - Theranostics, 2020 - ncbi.nlm.nih.gov
Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-specific
membrane antigen (PSMA) in vivo, which is the target molecule of 177 Lu-PSMA-617 (Lu-PSMA…
membrane antigen (PSMA) in vivo, which is the target molecule of 177 Lu-PSMA-617 (Lu-PSMA…